46 related articles for article (PubMed ID: 2643391)
1. [Phase I study and early phase II of SM-108 (4-carbamoylimidazolium-5-olate) in lung cancer. SM-108 Study Group].
Kimura K; Suzuoki Y; Ogawa M; Miyazaki T; Uzuka Y; Sakai Y; Ohno R; Yamada K; Ota K; Yoshida T
Gan To Kagaku Ryoho; 1989 Jan; 16(1):113-21. PubMed ID: 2643391
[TBL] [Abstract][Full Text] [Related]
2. [Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies].
Kimura K; Yamada K; Uzuka Y; Masaoka T; Hirano M; Ohno R; Ogawa M
Gan To Kagaku Ryoho; 1989 Jan; 16(1):123-30. PubMed ID: 2643392
[TBL] [Abstract][Full Text] [Related]
3. [Phase I study of raltitrexed (ZD-1694)].
Horikoshi N; Aiba K; Fukuoka M; Akazawa S; Sakata Y; Furuse K; Kanamaru R; Kudoh S; Konishi T; Kurihara M; Niitani H; Furue H; Tsukagoshi S; Taguchi T; Yoshida S; Ota K; Kotake T; Wakui A
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
[TBL] [Abstract][Full Text] [Related]
4. [Phase I study of CI-898. CI-898 Study Group].
Taguchi T; Tsukagoshi S; Furue H; Niitani H; Ohta K; Ariyoshi H; Hasegawa K; Majima H; Nakao I; Yasutomi M
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1599-612. PubMed ID: 1831340
[TBL] [Abstract][Full Text] [Related]
5. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
6. [Antitumor activities of orally administered 4-carbamoylimidazolium-5-olate (SM-108)].
Nakamura M; Fukui M; Morisada S; Inaba M; Tsukagoshi S; Sakurai Y
Gan To Kagaku Ryoho; 1985 Oct; 12(10):2030-6. PubMed ID: 4051519
[TBL] [Abstract][Full Text] [Related]
7. [SM-108].
Uzuka Y; Saito Y
Gan No Rinsho; 1985 May; 31(6 Suppl):757-66. PubMed ID: 4032756
[TBL] [Abstract][Full Text] [Related]
8. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
9. [Phase I and pharmacokinetic study of SM-5887 by 5-day schedule].
Inoue K; Matsumura A; Horikoshi N; Aiba K; Mukaiyama T; Matsumura T; Ogihara A; Sumida T; Ogawa M
Gan To Kagaku Ryoho; 1992 Apr; 19(4):477-82. PubMed ID: 1558397
[TBL] [Abstract][Full Text] [Related]
10. [Clinical trial of SM-108 in myeloproliferative disorders].
Nishikawa M; Morita K; Sekine T; Takeda M; Tamaki S; Katayama N; Kobayashi T; Mukai K; Tanaka H; Minami N
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3078-82. PubMed ID: 3314714
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
12. [Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Nakao I; Saito T; Kimura K; Wakui A; Yokoyama M; Kanamaru R; Furue H; Komita T; Ohta K; Murakami M
Gan To Kagaku Ryoho; 1985 Oct; 12(10):2037-43. PubMed ID: 2932058
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
[TBL] [Abstract][Full Text] [Related]
14. Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors.
Yoshida N; Nakamura M; Fukui M; Morisada S; Ogino S; Inaba M; Tsukagoshi S; Sakurai Y
Cancer Res; 1983 Dec; 43(12 Pt 1):5851-6. PubMed ID: 6640536
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
17. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
[TBL] [Abstract][Full Text] [Related]
18. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
[TBL] [Abstract][Full Text] [Related]
19. Pilot trial of a combination comprising of consecutive oral administration of UFT, and two-divided administration of CDDP in non-small cell lung cancer.
Gemma A; Kudoh S; Yoshimura A; Ono Y; Takenaka K; Hayashihara K; Hino M; Shibuya M; Niitani H
Anticancer Res; 1995; 15(6B):2691-5. PubMed ID: 8669849
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
